Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography

Atherosclerosis

Volumn 207, Issue 1, 2009, Pages 261-265

  Cavusoglu, Erdal ^a,b   Marmur, Jonathan D ^a   Chhabra, Sandeep ^a   Chopra, Vineet ^b   Eng, Calvin ^b   Jiang, Xian Cheng ^c  

^a SUNY Downstate Medical Center   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Inflammation; Left ventricular systolic dysfunction; Phospholipid transfer protein

Indexed keywords

PHOSPHOLIPID TRANSFER PROTEIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE MARKER; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SYSTOLIC DYSFUNCTION;

AGED; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DATABASES AS TOPIC; DIASTOLE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHOSPHOLIPID TRANSFER PROTEINS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70350570581     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.04.011     Document Type: Article

References (35)

1. Tall A.R., Jiang X., Luo Y., and Silver D. George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2000 20 (1999) 1185-1188
2. Jiang X.C., Qin S., Qiao C., et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 7 (2001) 847-852
3. van Haperen R., van Tol A., van Gent T., et al. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 277 (2002) 48938-48943
4. Jiang X.C., Tall A.R., Qin S., et al. Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem 277 (2002) 31850-31856
5. Yang X.P., Yan D., Qiao C., et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 23 (2003) 1601-1607
6. Schlitt A., Bickel C., Thumma P., et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 23 (2003) 1857-1862
7. Tahvanainen E., Jauhiainen M., Funke H., Vartiainen E., Sundvall J., and Ehnholm C. Serum phospholipid transfer protein activity and genetic variation of the PLTP gene. Atherosclerosis 146 (1999) 107-115
8. Dullaart R.P., Sluiter W.J., Dikkeschei L.D., Hoogenberg K., and Van Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 24 (1994) 188-194
9. Riemens S.C., van Tol A., Sluiter W.J., and Dullaart R.P. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese Type II diabetic patients. Diabetologia 41 (1998) 929-934
10. Colhoun H.M., Scheek L.M., Rubens M.B., et al. Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. Diabetes 50 (2001) 652-659
11. Tan K.C., Shiu S.W., Wong Y., and Tam S. Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 178 (2005) 365-370
12. Schneider M., Verges B., Klein A., et al. Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. Diabetes 53 (2004) 2633-2639
13. Yan D., Navab M., Bruce C., Fogelman A.M., and Jiang X.C. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J Lipid Res 45 (2004) 1852-1858
14. Schlitt A., Liu J., Yan D., Mondragon-Escorpizo M., Norin A.J., and Jiang X.C. Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochim Biophys Acta 1733 (2005) 187-191
15. Shelly L., Royer L., Sand T., Jensen H., and Luo Y. Phospholipid transfer protein deficiency ameliorates diet-induced hypercholesterolemia and inflammation in mice. J Lipid Res 49 (2008) 773-781
16. Redfield M.M., Jacobsen S.J., Burnett Jr. J.C., Mahoney D.W., Bailey K.R., and Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289 (2003) 194-202
17. Adams Jr. K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005) 209-216
18. Taegtmeyer H., McNulty P., and Young M.E. Adaptation and maladaptation of the heart in diabetes. Part I. General concepts. Circulation 105 (2002) 1727-1733
19. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. N Engl J Med 347 (2002) 305-313
20. Maeda K., Tsutamoto T., Wada A., et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36 (2000) 1587-1593
21. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., and Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103 (2001) 2055-2059
22. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102 (2000) 3060-3067
23. Tsutamoto T., Hisanaga T., Wada A., et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31 (1998) 391-398
24. Feldman A.M., Combes A., Wagner D., et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35 (2000) 537-544
25. Tsutsui T., Tsutamoto T., Wada A., et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 39 (2002) 957-962
26. Hare J.M., and Johnson R.J. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation 107 (2003) 1951-1953
27. Cavusoglu E., Ruwende C., Chopra V., et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 27 (2006) 2300-2309
28. Tall A.R., Krumholz S., Olivecrona T., and Deckelbaum R.J. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res 26 (1985) 842-851
29. Jauhiainen M., Metso J., Pahlman R., Blomqvist S., van Tol A., and Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 268 (1993) 4032-4036
30. Cavusoglu E., Chopra V., Gupta A., et al. Usefulness of the white blood cell count as a predictor of angiographic findings in an unselected population referred for coronary angiography. Am J Cardiol 98 (2006) 1189-1193
31. Cavusoglu E., Chopra V., Battala V., et al. Baseline plasma adiponectin levels as a predictor of left ventricular systolic dysfunction in patients referred for coronary angiography. Am J Cardiol 101 (2008) 1073-1078
32. Vikstedt R., Metso J., Hakala J., Olkkonen V.M., Ehnholm C., and Jauhiainen M. Cholesterol efflux from macrophage foam cells is enhanced by active phospholipid transfer protein through generation of two types of acceptor particles. Biochemistry 46 (2007) 11979-11986
33. de Vries R., Dallinga-Thie G.M., Smit A.J., Wolffenbuttel B.H., van Tol A., and Dullaart R.P. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 49 (2006) 398-404
34. Yatsuya H., Tamakoshi K., Hattori H., et al. Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases. Circ J 68 (2004) 11-16
35. Schgoer W., Mueller T., Jauhiainen M., et al. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis 196 (2008) 219-226